RRML - The Role of Prostate-Specific Antigen (PSA) in Prostate Cancer Screening

ISSN online: 2284-5623

ISSN-L: 1841-6624

Impact factor (2019): 0.945

Rejection rate (2020): 75%

Română English

Clarivate analytics (ISI) Impact factor

Advanced search

Top 10 downloaded articles
- January 2021 -
Evaluation of Plasma AA/DHA+EP... 11
The Role of MiR-124 in Bladder... 10
Molecular diagnostic of Ureapl... 9
Difficult to treat Proteeae st... 8
Assessment on the influence of... 8
The positive rate of IgM and I... 8
Romanian Review of Laboratory ... 7
Assessment of circulating tumo... 6
LSM3, NDUFB3, and PTGS2 may be... 5
Antibacterial and antitumor ac... 5

Log in

Concept, Design & Programming
Dr. Adrian Man

Nr. 22(2)/2014 DOI:10.2478/rrlm-2014-0024

The Role of Prostate-Specific Antigen (PSA) in Prostate Cancer Screening

Traian Vasile Constantin, Victor Lucian Mădan, Maria-Magdalena Constantin, Silviu-Horia Morariu, Bogdan Braticevici


Prostate cancer is, after lung cancer, the most common malignant disease diagnosed in the male population. The introduction into the practice used during the 80’s and 90’s of the determination of serum Prostate-Specific Antigen (PSA) levels, as a component of screening for prostate cancer, was a turning point in the medical practice. Due to this enzyme produced exclusively by the prostate gland, the prostate cancer detection rate (in curative, intracapsular stages) improved significantly. Serum PSA is a better predictive factor for prostate cancer (PC) than digital rectal examination or transrectal prostatic ultrasound.

Keywords: Prostate-specific antigen, prostate cancer, benign prostatic hyperplasia

Received: 16.1.2014
Accepted: 1.6.2014
Published: 9.6.2014

  PDF Download full text PDF
(260 KB)
How to cite
Constantin TV, Mădan VL, Constantin MM, Morariu SH, Braticevici B. The Role of Prostate-Specific Antigen (PSA) in Prostate Cancer Screening. Rev Romana Med Lab. 2014;22(2):275-81. DOI:10.2478/rrlm-2014-0024